Expert Review of Gastroenterology & Hepatology最新文献_第6页

The emerging roles of intestinal organoid models in inflammatory bowel disease research. 肠道类器官模型在炎症性肠病研究中的新作用。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-01 Epub Date: 2026-02-22 DOI: 10.1080/17474124.2026.2635421

Steven T Leach, Tess Wheeler, Nerissa Bowcock, Alan Aitchison, Daniel A Lemberg, Andrew S Day

{"title":"The emerging roles of intestinal organoid models in inflammatory bowel disease research.","authors":"Steven T Leach, Tess Wheeler, Nerissa Bowcock, Alan Aitchison, Daniel A Lemberg, Andrew S Day","doi":"10.1080/17474124.2026.2635421","DOIUrl":"10.1080/17474124.2026.2635421","url":null,"abstract":"Introduction: The chronic immune mediated gastrointestinal disease, Inflammatory Bowel Disease (IBD), is increasing in prevalence. However, IBD pathogenesis remains unclear despite decades of research. Therefore, new methods and models of disease are required to gain further insights into IBD pathogenesis. Recent advances in stem cell culture technology now allows for the routine in vitro culture of stem cells derived from an individual. These in vitro stem cells can differentiate into cell-types and cell clusters that resemble the tissue origin of the stem cells. These cell clusters have been termed organoids.Areas covered: Following review of recent available literature, the goal of this review was to specifically focus on intestinal organoids and provide basic methodology of organoid derivation. The review will also discuss the current and potential applications of intestinal organoid models in Gastroenterology research including IBD pathogenesis, host-microbiome interactions, therapeutic response and drug discovery, very-early onset IBD, organ-on-a-chip and bioprinted models.Expert opinion: Organoids offer tangible benefits for improved patient outcomes, particularly with respect to personalized medicine approaches to IBD management.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"247-256"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease - paving a path forward. 口服万古霉素治疗原发性硬化性胆管炎及相关炎症性肠病——铺平了前进的道路。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-01 Epub Date: 2026-03-10 DOI: 10.1080/17474124.2026.2635420

Kevin M Johnson, John Grady, Richard Kellermayer, Harland S Winter, James H Tabibian, Cynthia W Buness, Ryan Fischer, Ayesha Shah, Parambir S Dulai, Amol S Rangnekar, Leina Alrabadi, Shamita B Shah, Gerald Holtmann, Laura Räisänen, Peter Lewindon, Ahmad H Ali

{"title":"Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease - paving a path forward.","authors":"Kevin M Johnson, John Grady, Richard Kellermayer, Harland S Winter, James H Tabibian, Cynthia W Buness, Ryan Fischer, Ayesha Shah, Parambir S Dulai, Amol S Rangnekar, Leina Alrabadi, Shamita B Shah, Gerald Holtmann, Laura Räisänen, Peter Lewindon, Ahmad H Ali","doi":"10.1080/17474124.2026.2635420","DOIUrl":"10.1080/17474124.2026.2635420","url":null,"abstract":"Introduction: Primary sclerosing cholangitis (PSC) is a fibro-inflammatory cholangiopathy strongly associated with inflammatory bowel disease (PSC-IBD). With no approved PSC therapy, clinicians face uncertainty about oral vancomycin (OV) as a therapeutic option. This review synthesizes clinical effectiveness evidence alongside mechanistic data.Areas covered: We searched PubMed/Google Scholar for studies of vancomycin in PSC from 1998 through November, 2025. OV shows consistent IBD benefits and variable liver responses. In PSC-IBD, clinical and endoscopic remission occurred in 60% at 6 months and in 71% at 12 months in a pediatric cohort; in an adult single-arm study (n = 15), 80% achieved endoscopic remission at 4 weeks with universal mucosal healing, reductions in fecal calprotectin and Mayo scores, and relapse after withdrawal. For liver disease, a pediatric open-label cohort (n = 45) reported ≥50% declines in gamma-glutamyl transferase in 82%; in an adult pilot randomized controlled trial, alkaline phosphatase fell 46% at 12 weeks. Imaging/histology improved as evidenced by MRCP in 26/34 large-duct PSC and reduced portal/periportal inflammation in 11/12 small-duct PSC. No vancomycin-resistant enterococci development has been reported.Expert opinion: OV appears effective for colitis control in PSC-IBD. Differences in observed liver outcomes across studies likely reflect variation in treatment duration, dose, and endpoint selection. Liver responses may depend on higher doses. Cross-specialty guidance and pragmatic, integrated trials are needed.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"233-246"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging in MASLD. MASLD成像。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-01 Epub Date: 2026-02-28 DOI: 10.1080/17474124.2026.2636184

Sudhakar K Venkatesh

{"title":"Imaging in MASLD.","authors":"Sudhakar K Venkatesh","doi":"10.1080/17474124.2026.2636184","DOIUrl":"10.1080/17474124.2026.2636184","url":null,"abstract":"Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease (CLD) globally, with increasing prevalence and risk of progression to cirrhosis, hepatocellular carcinoma, and liver-related mortality. Early detection and accurate staging are essential to guide interventions as new therapies emerge.Areas covered: This review discusses imaging-based evaluation of MASLD, emphasizing its role in assessing steatosis, fibrosis, and complications of CLD. A literature search of PubMed and Scopus identified peer-reviewed publications from 2000 to the present, including large clinical trials, expert reviews, and major hepatology and imaging guidelines. Key modalities evaluated include ultrasound, computed tomography, and magnetic resonance imaging. Advanced quantitative techniques, such as transient elastography, shear wave elastography, MR elastography, and MRI proton density fat fraction, are summarized. Their role in longitudinal monitoring and prediction of liver-related outcomes is discussed. Advances in ultrasound and emerging imaging biomarkers, including sarcopenia and visceral adiposity, are also briefly discussed.Expert opinion: Imaging is central to precision hepatology in MASLD, enabling comprehensive, noninvasive assessment and integration with clinical data for risk stratification. The integration of clinical data, imaging findings, and elastography will further enhance individualized care and treatment monitoring.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"257-272"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates on intestinal failure management. 肠衰竭管理的最新进展。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-01 Epub Date: 2026-02-10 DOI: 10.1080/17474124.2026.2628008

M V Teso, T E Conley, S Lal

{"title":"Updates on intestinal failure management.","authors":"M V Teso, T E Conley, S Lal","doi":"10.1080/17474124.2026.2628008","DOIUrl":"10.1080/17474124.2026.2628008","url":null,"abstract":"Introduction: Chronic intestinal failure (CIF) is a rare condition characterized by inadequate intestinal absorption requiring long-term parenteral nutrition (PN). Given etiological shifts and expanding therapeutic options, we provide an updated review covering CIF definitions, epidemiology and multidisciplinary management in adults, based on recently published studies (2012-2025).Areas covered: We conducted a scoping review of recent literature, registry data and guideline recommendations to summarize contemporary trends in CIF.Short bowel syndrome remains the leading cause of CIF, though the etiological profile has shifted toward surgical complications and active malignancy. Advances in the multidisciplinary and multimodal management with safer PN formulations, chyme reinfusion therapy, and disease-modifying pharmacotherapies such as glucagon-like peptide-2 analogues have transformed outcomes, while intestinal transplantation is reserved for selected cases. Preventing complications and focusing on quality of life (QoL) are central to long-term management.Expert opinion: CIF prevalence continues to rise worldwide, though accurate data remain inconsistent. As patient complexity rises, long-term outcomes increasingly depend on complication prevention and centralized, multidisciplinary care delivered by expert centers. In the next five years, the convergence of pharmacological, surgical, digital and organizational innovations will enhance enteral autonomy, reduce PN-related complications and improve patients' QoL, providing a more equitable and effective model of CIF care worldwide.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"205-218"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Altered gastrointestinal motility after bariatric surgery: consequences, complications and clinical considerations. 减肥手术后胃肠运动改变：后果、并发症和临床考虑。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-01 Epub Date: 2025-11-25 DOI: 10.1080/17474124.2025.2593454

Gwen M C Masclee, Adrian A M Masclee

{"title":"Altered gastrointestinal motility after bariatric surgery: consequences, complications and clinical considerations.","authors":"Gwen M C Masclee, Adrian A M Masclee","doi":"10.1080/17474124.2025.2593454","DOIUrl":"10.1080/17474124.2025.2593454","url":null,"abstract":"Introduction: Bariatric surgical interventions such as laparoscopic sleeve gastrectomy (LSG), Roux-en-Y gastric bypass (RYGB), One-Anastomosis Gastric Bypass (OAGB) and Laparoscopic Adjustable Gastric Banding (LAGB) have proven to be effective in long-term management of obesity. These procedures result in changes in anatomy and in motor and secretory function of the gastrointestinal (GI) tract.Areas covered: This review covers the changes in gastrointestinal motility and their consequences observed after the various types of bariatric surgery. A systematic literature search on motility disorders of esophagus, stomach, small and large bowel until August 2025 was performed (PubMed).Expert opinion: Esophageal motility: a higher prevalence of dysphagia and post-obesity surgery esophageal dysfunction (POSED) is seen after bariatric surgery due to gastric restriction (intragastric high-pressure zone, esophageal outflow obstruction). Gastroesophageal reflux disease (GERD) is already common in people with obesity and may significantly increase after bariatric surgery depending on the type of procedure (LSG, not RYGB). Gastrointestinal motility: bariatric surgery results in significant acceleration of gastric emptying and of small intestinal transit (LSG > RYGB) with delay in colonic transit. Clinical considerations relevant for preoperative work-up, selection of bariatric procedure-type and postoperative follow-up of GI-motility disorders induced by bariatric surgery have been provided.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"273-288"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endoscopic considerations for patients with gastroesophageal reflux disease. 胃食管反流病患者的内镜注意事项。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-01 Epub Date: 2026-02-09 DOI: 10.1080/17474124.2026.2629609

Amir Farah, Amir Mari

引用次数: 0

The role of endoscopic therapies for patients with metabolic dysfunction-associated steatotic liver disease (MASLD). 内镜治疗在代谢功能障碍相关脂肪变性肝病（MASLD）患者中的作用

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-01 Epub Date: 2026-02-16 DOI: 10.1080/17474124.2026.2632873

Joan Llach, Anna Soria, Isabel Graupera, Andrés Cardenas

{"title":"The role of endoscopic therapies for patients with metabolic dysfunction-associated steatotic liver disease (MASLD).","authors":"Joan Llach, Anna Soria, Isabel Graupera, Andrés Cardenas","doi":"10.1080/17474124.2026.2632873","DOIUrl":"10.1080/17474124.2026.2632873","url":null,"abstract":"Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major public health challenge closely linked to obesity and metabolic syndrome. Effective, durable weight-loss strategies are needed to modify its natural history, particularly in patients at high surgical risk or with limited response to pharmacotherapy.Areas covered: This review summarizes current and emerging weight-loss approaches for MASLD, focusing on pharmacological therapies, bariatric surgery and endoscopic interventions. From an expert narrative perspective, we discuss key randomized and observational studies on endoscopic sleeve gastroplasty (ESG), cost-effectiveness analyses, and the limited evidence in patients with compensated advanced chronic liver disease (cACLD), who represent an unmet need.Expert opinion: ESG could be a promising, minimally invasive option for patients with MASLD who are ineligible for bariatric surgery or refractory to medical therapy. Early data suggest clinically meaningful weight loss, metabolic improvement, and a favorable safety profile, but long-term outcomes and direct histological benefits remain to be defined, particularly in patients with advanced fibrosis or cACLD. Combining ESG with pharmacological agents, such as GLP-1 receptor agonists, theoretically may enhance outcomes and deserves further study. Well-designed trials are required to better define the role of ESG in MASLD management and its potential integration into clinical practice.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"219-231"},"PeriodicalIF":3.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146194297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Occult hepatitis B infection - unveiling clinical burden and new diagnostic strategies. 隐性乙型肝炎感染——揭示临床负担和新的诊断策略。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-02-01 Epub Date: 2026-01-02 DOI: 10.1080/17474124.2025.2611857

Vicente Soriano, Rocío González, Luisa Barea, Víctor Moreno-Torres, Ana Arruga, Ana Lafuente, Antonio Aguilera

{"title":"Occult hepatitis B infection - unveiling clinical burden and new diagnostic strategies.","authors":"Vicente Soriano, Rocío González, Luisa Barea, Víctor Moreno-Torres, Ana Arruga, Ana Lafuente, Antonio Aguilera","doi":"10.1080/17474124.2025.2611857","DOIUrl":"10.1080/17474124.2025.2611857","url":null,"abstract":"Introduction: Occult B infection (OBI) represents a mild form of hepatitis B characterized by low-level HBV-DNA in the absence of positive serum HBsAg. OBI is associated with liver disease and HBV transmissibility, although to a lesser extent than overt (HBsAg+) chronic hepatitis B.Areas covered: Residual HBV replication in the liver of OBI patients has been associated with i) increased risk for cirrhosis and/or liver cancer, ii) HBV transmission to recipients of organs or hemoderivates, iii) overt HBV reactivation under immunosuppression, and iv) extrahepatic manifestations.We searched PubMed with the keywords \"occult hepatitis B,\" \"occult B infection\" or \"OBI.'Expert opinion: The WHO has called for reducing 90% new HBV infections and 65% HBV-related mortality by 2030. The persistence of low-level virus replication in persons who cleared serum HBsAg is challenging. OBI misdiagnosis has emerged as a major obstacle for global HBV elimination. Efforts for unveiling OBI carriers are warranted, increasing clinical suspicion and expanding testing. New diagnostic tools, including more sensitive HBsAg and HBV-DNA tests and novel HBV-RNA and HBcrAg assays, may help unveil OBI carriers. Furthermore, point-of-care HBV-DNA assays will allow testing larger populations for OBI. New antivirals should target this form of hidden hepatitis B.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"71-80"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing current limitations of colonoscopy for colorectal cancer screening. 解决目前结肠镜检查在结直肠癌筛查中的局限性。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-02-01 Epub Date: 2026-02-10 DOI: 10.1080/17474124.2026.2628015

Aastha Bharwad, Eric Yoon, Brooks D Cash

{"title":"Addressing current limitations of colonoscopy for colorectal cancer screening.","authors":"Aastha Bharwad, Eric Yoon, Brooks D Cash","doi":"10.1080/17474124.2026.2628015","DOIUrl":"10.1080/17474124.2026.2628015","url":null,"abstract":"Introduction: Colonoscopy is widely accepted as the gold standard modality for colorectal cancer (CRC) screening and polyp surveillance. Colonoscopy has been shown to decrease the incidence and mortality of CRC and is the ground truth test to which new and alternative CRC screening modalities are compared. In the U.S., more than 15 million colonoscopies are performed yearly for CRC screening, and the procedure is accepted as safe and effective. However, there are important limitations of colonoscopy for CRC screening that remain unresolved and continue to limit the maximal usefulness of this procedure.Areas covered: This article will highlight some of the recognized limitations of colonoscopy for CRC screening, including high costs, access and compliance barriers, preparation difficulties, complications, and performance variability.Expert opinion: Colonoscopy is the gold-standard test for CRC screening but is subject to significant limitations. There have been important efforts directed toward mitigating the limitations of colonoscopy for CRC screening, and these efforts have the potential to expand and enhance the use of colonoscopy as a CRC screening test in the future.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"107-117"},"PeriodicalIF":3.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiparametric intestinal ultrasound in inflammatory bowel diseases: a narrative review. 炎症性肠病的多参数肠超声：叙述综述。

IF 3.3 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-02-01 Epub Date: 2026-02-16 DOI: 10.1080/17474124.2026.2624595

Giovanni Cataletti, Daniele Gridavilla, Marta Casella, Gabriele Natalello, Giovanni Maconi

{"title":"Multiparametric intestinal ultrasound in inflammatory bowel diseases: a narrative review.","authors":"Giovanni Cataletti, Daniele Gridavilla, Marta Casella, Gabriele Natalello, Giovanni Maconi","doi":"10.1080/17474124.2026.2624595","DOIUrl":"10.1080/17474124.2026.2624595","url":null,"abstract":"Introduction: Multiparametric intestinal ultrasound (MPUS) has emerged as a valuable, noninvasive tool for the diagnosis, monitoring, and phenotyping of inflammatory bowel diseases (IBD), offering real-time assessment of bowel wall structure, vascularity, and stiffness.Areas covered: This review discusses the latest advancements in intestinal ultrasound, including contrast-enhanced ultrasound (CEUS), elastography, and ultrasound microvascular imaging (UMI). These techniques enhance the characterization of inflammation and fibrosis, help differentiate between inflammatory and fibrotic strictures, detect complications such as abscesses or phlegmons, and monitor therapeutic response. The narrative is based on a comprehensive analysis of recent literature identified through a PubMed search conducted up to September 2025. with a focus on clinical applicability, technical methodology, and current evidence supporting each modality.Expert opinion: MPUS represents a transformative evolution in IBD imaging, particularly in point-of-care and longitudinal disease management. Despite its strong potential, widespread adoption is limited by technical variability, operator dependency, and lack of standardization. Future integration into clinical practice will require multicenter validation, standardized protocols, and training programs. The development of AI-assisted tools and targeted CEUS may soon elevate MPUS from a structural to a functional and molecular imaging modality, opening the door to personalized, precision-based IBD care.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"135-146"},"PeriodicalIF":3.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0